

**Table 1. Overview of TEAEs and most common TEAEs (occurring in  $\geq 10\%$  of patients in any subgroup) (Safety Analysis Set)**

	Perampanel with concurrent use of levetiracetam		Perampanel with prior use of levetiracetam		Perampanel with no use of levetiracetam	
	With EIASMs <sup>a</sup> (n=266)	With non-EIASMs (n=213)	With EIASMs <sup>a</sup> (n=45)	With non-EIASMs (n=26)	With EIASMs <sup>a</sup> (n=551)	With non-EIASMs (n=288)
<b>TEAEs, n (%)</b>	201 (75.6)	185 (86.9)	37 (82.2)	21 (80.8)	417 (75.7)	233 (80.9)
<b>Treatment-related TEAEs, n (%)</b>	162 (60.9)	156 (73.2)	31 (68.9)	18 (69.2)	317 (57.5)	185 (64.2)
<b>Serious TEAEs, n (%)</b>	14 (5.3)	13 (6.1)	4 (8.9)	3 (11.5)	28 (5.1)	14 (4.9)
<b>Most common TEAEs (<math>\geq 10\%</math>), n (%)</b>						
Dizziness	83 (31.2)	86 (40.4)	21 (46.7)	6 (23.1)	162 (29.4)	82 (28.5)
Somnolence	42 (15.8)	48 (22.5)	4 (8.9)	3 (11.5)	66 (12.0)	56 (19.4)
Nasopharyngitis	26 (9.8)	25 (11.7)	0 (0.0)	2 (7.7)	38 (6.9)	22 (7.6)
Headache	21 (7.9)	16 (7.5)	7 (15.6)	5 (19.2)	61 (11.1)	27 (9.4)
Fatigue	14 (5.3)	26 (12.2)	2 (4.4)	6 (23.1)	32 (5.8)	19 (6.6)
Irritability	14 (5.3)	23 (10.8)	5 (11.1)	4 (15.4)	29 (5.3)	18 (6.3)
Nausea	9 (3.4)	12 (5.6)	2 (4.4)	3 (11.5)	26 (4.7)	16 (5.6)
Fall	7 (2.6)	12 (5.6)	2 (4.4)	3 (11.5)	20 (3.6)	9 (3.1)
Contusion	8 (3.0)	6 (2.8)	0 (0.0)	3 (11.5)	8 (1.5)	5 (1.7)
Arthralgia	4 (1.5)	4 (1.9)	1 (2.2)	3 (11.5)	4 (0.7)	3 (1.0)

Patients with  $\geq 2$  TEAEs in the same system organ class (or with the same preferred term) are counted only once for that system organ class (or preferred term)

<sup>a</sup>EIASMs are defined as carbamazepine, eslicarbazepine, oxcarbazepine, and phenytoin

EIASM, enzyme-inducing anti-seizure medication; TEAE, treatment-emergent adverse event